focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.10
Ask: 3.40
Change: -0.10 (-2.99%)
Spread: 0.30 (9.677%)
Open: 3.35
High: 3.35
Low: 3.25
Prev. Close: 3.35
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

10 Jan 2018 15:19

RNS Number : 5221B
Allergy Therapeutics PLC
10 January 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Allergy Therapeutics PLC

LEI: 213800PQ7AHK7KGVOE23

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Placing of Shares

3. Details of person subject to the notification obligationiv

Name

Invesco Ltd.

City and country of registered office (if applicable)

1555 Peachtree Street NE, Suite 1800,

Atlanta, GA 30309 United States

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

09-01-2018

6. Date on which issuer notified (DD/MM/YYYY):

10-01-2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.81%

0

4.81%

594,117,768

Position of previous notification (if

applicable)

5.62%

0

5.62%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

 

GB00B02LCQ05

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

28,618,373

4.81%

SUBTOTAL 8. A

28,618,373

4.81%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Invesco Asset

Management Limited.

4.81%

0

4.81%

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

Invesco (UK) Ltd.

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

 

Place of completion

Henley-on-Thames

Date of completion

10-01-2018

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEASFEFFPPEFF
Date   Source Headline
23rd May 201211:23 amRNSVoluntary recall of Anapen by Lincoln Medical
17th May 20124:51 pmRNSHolding(s) in Company
17th May 20124:51 pmRNSHolding(s) in Company
16th May 201211:11 amRNSTotal Voting Rights
2nd May 20123:33 pmRNSBoard Appointment
24th Apr 201212:31 pmRNSHolding(s) in Company
20th Apr 20128:01 amRNSConcert Party Shareholding
20th Apr 20128:01 amRNSDirector/PDMR Shareholding
19th Apr 20123:05 pmRNSResult of AGM
18th Apr 20127:00 amRNSResult of Offer
30th Mar 20127:02 amRNSGrant of Options
30th Mar 20127:01 amRNSFundraising Announcement
30th Mar 20127:00 amRNSHalf Yearly Report
14th Mar 20129:23 amRNSNotice of results and shareholder update
21st Feb 20126:12 pmRNSHolding(s) in Company
21st Feb 20126:11 pmRNSHolding(s) in Company
6th Dec 20117:00 amRNSAnapen® 500mcg epinephrine auto-injector
28th Nov 20117:00 amRNSRegulatory update PEI FDA
16th Nov 20115:20 pmRNSAGM Statement
20th Oct 20116:24 pmRNSAnnual Financial Report
29th Sep 201112:45 pmRNSProvisional Grant of Options
19th Sep 20117:00 amRNSFinal Results
19th Sep 20117:00 amRNSDistribution Agreement
8th Sep 20115:06 pmRNSHolding(s) in Company
7th Sep 20117:00 amRNSNotice of Results
23rd Aug 20119:35 amRNSForm 8.3 - [Allergy Therapeutics]
23rd Aug 20117:00 amRNSAllergy Therapeutics enters Latin America
22nd Aug 201112:03 pmRNSForm 8.3 - [Allergy Therapeutics Plc]
8th Jun 20117:00 amRNSRegulatory Update
28th Apr 20117:00 amRNSTotal Voting Rights
26th Apr 20117:00 amRNSFDA Update
20th Apr 20112:59 pmRNSExercise of Options
11th Apr 20114:31 pmRNSHolding(s) in Company
7th Apr 20117:00 amRNSGrass MATA MPL dossier submitted in Switzerland
30th Mar 20116:19 pmRNSDirector/PDMR Shareholding
29th Mar 20113:19 pmRNSDirector/PDMR Shareholding
29th Mar 20113:17 pmRNSDirector/PDMR Shareholding
28th Mar 20117:02 amRNSU.S. regulatory update
28th Mar 20117:00 amRNSHalf Yearly Report
9th Feb 201110:32 amRNSHolding(s) in Company
9th Feb 201110:31 amRNSHolding(s) in Company
1st Dec 20107:00 amRNSTen further MAAs submitted in Germany
18th Nov 201011:52 amRNSResult of AGM
20th Oct 20108:06 amRNSAnnual Financial Report
4th Oct 20109:45 amRNSDirector/PDMR Shareholding
30th Sep 20103:21 pmRNSDirectorate Change
20th Sep 20107:00 amRNSFinal Results
26th Jul 201010:06 amRNSHolding(s) in Company
22nd Jul 201012:24 pmRNSTrading Statement
19th Jul 201012:58 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.